The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor.

[1]  L. Lind,et al.  CRP and IL‐6 concentrations are associated with poor glycemic control despite preserved β‐cell function during the first year after diagnosis of type 1 diabetes , 2004, Diabetes/metabolism research and reviews.

[2]  M. S. South,et al.  Assessment of Bleeding Propensity in Non-Human Primates by Combination of Selective Tissue Factor/VIIa Inhibition and Aspirin Compared to Warfarin and Aspirin Treatment , 2004, Pharmacology.

[3]  M. S. South,et al.  Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor VIIa Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[5]  T. van der Poll,et al.  Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects , 2003, Clinical Diagnostic Laboratory Immunology.

[6]  K. Malm,et al.  Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. , 2003, Plastic and Reconstructive Surgery.

[7]  H. Prydz,et al.  Factor VIIa Induces Tissue Factor-dependent Up-regulation of Interleukin-8 in a Human Keratinocyte Line* , 2002, The Journal of Biological Chemistry.

[8]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[9]  R. Peters,et al.  Tissue factor and coronary artery disease. , 2002, Cardiovascular research.

[10]  Richard S. Larson,et al.  Immobilized IL-8 Triggers Progressive Activation of Neutrophils Rolling In Vitro on P-Selectin and Intercellular Adhesion Molecule-11 , 2001, The Journal of Immunology.

[11]  W. Konigsberg,et al.  The TF:VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis , 2001, Thrombosis and Haemostasis.

[12]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  N. Mackman,et al.  Measurement of Tissue Factor Activity in Whole Blood , 2000, Thrombosis and Haemostasis.

[14]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[15]  H. Prydz,et al.  Binding of Factor VIIa to Tissue Factor on Keratinocytes Induces Gene Expression* , 2000, The Journal of Biological Chemistry.

[16]  S. Bolling,et al.  Surgical approaches to dilated cardiomyopathy , 2000, Current cardiology reports.

[17]  X. Han,et al.  Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  M. Albert,et al.  The role of C-reactive protein in cardiovascular disease risk , 1999, Current cardiology reports.

[19]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[20]  V. Fuster,et al.  Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. , 1999, Circulation.

[21]  E. Chi,et al.  Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. , 1998, The Journal of thoracic and cardiovascular surgery.

[22]  A. Chang,et al.  Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. , 1998, Blood.

[23]  I. Tsuji,et al.  Comparison of plasma tissue factor levels in unstable and stable angina pectoris. , 1998, The American journal of cardiology.

[24]  U. Rüther,et al.  Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. , 1997, The Biochemical journal.

[25]  I. Tsuji,et al.  Increased plasma tissue factor levels in acute myocardial infarction. , 1997, American heart journal.

[26]  A. Pasternack,et al.  Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. , 1996, European heart journal.

[27]  D. Thomas,et al.  Venous Thrombosis and the “Wessler Test” , 1996, Thrombosis and Haemostasis.

[28]  K. Channon,et al.  Differential Expression of Tissue Factor Protein in Directional Atherectomy Specimens From Patients With Stable and Unstable Coronary Syndromes , 1995 .

[29]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[30]  T. Edgington,et al.  Structural biology of tissue factor, the initiator of thrombogenesis in vivo 1 , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  G. Ciliberto,et al.  Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6. , 1989, The EMBO journal.

[32]  E. Downs,et al.  Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP). , 1986, Lymphokine research.